Objectives: Angelman syndrome (AS) is a neurogenetic disorder associated with impaired expression of the ubiquitin-protein ligase E3A gene on chromosome 15. AS results in intellectual disability with limited expressive language, epilepsy, ataxia, sleep impairment, and problematic behavior which may include anxiety. Buspirone is a serotonin (5-HT)1A receptor partial agonist used in the treatment of anxiety disorders and may, therefore, have a treatment role for patients with AS.
Methods: We describe three patients who were given open-label buspirone for the treatment of behaviors thought to be related to anxiety.
Results: We found significant improvement in symptoms of anxiety with buspirone. Patients tolerated long-term usage of the medication.
Conclusion: The findings of this study suggest that buspirone may be effective for the amelioration of behaviors related to anxiety in patients with AS, and well tolerated. Limitations include the open-label nature of these treatments, the small sample size and the absence of a control group.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/YPG.0000000000000218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neurological Insights: Transient Unilateral Relative Afferent Pupillary Defect in the Context of Serotonin Syndrome.
Cureus
December 2024
Internal Medicine, Saint Joseph Hospital-Intermountain Health, Denver, USA.
The pupillary reflex is a complex physiological response involving both the eye and associated neural pathways. Relative afferent pupillary defects (RAPDs) can present due to various underlying pathologies, yet their occurrence in serotonin syndrome has been rarely documented. This report details the case of a 21-year-old non-binary individual with a history of bipolar disorder who presented to the emergency department following a polypharmacy overdose, including significant ingestion of sertraline, aripiprazole, and buspirone.
View Article and Find Full Text PDFEffect of Buspirone on Upper Gastrointestinal Disorders of Gut-Brain Interaction: A Systematic Review and Meta-analysis.
J Neurogastroenterol Motil
January 2025
Department of Gastroenterology, St Mark's Hospital, London, UK.
Background/aims: Buspirone shows promise in treating disorders of gut-brain interaction (DGBIs), particularly functional dyspepsia. However, findings have been mixed.
Methods: We systematically searched for prospective studies testing buspirone for any upper gastrointestinal DGBI in 4 databases (Cochrane, PubMed, Scopus, and PsycInfo).
Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms.
BMC Med
January 2025
Lurie Center for Autism, Massachusetts General Hospital, Lexington, MA, 02421, USA.
Background: The prevalence of autism spectrum disorder (ASD) has surged, with an estimated 1 in 36 eight-year-olds in the United States meeting criteria for ASD in 2020. Autistic individuals face elevated rates of co-occurring medical, psychiatric, and behavioral conditions compared to non-autistic individuals. The rising ASD-patient demand is increasingly outpacing the capacity of ASD-specialty clinics, resulting in urgent need for autism-competent providers in general practice settings.
View Article and Find Full Text PDFDietary Supplements for Weight Loss and Drug Interactions.
Pharmaceuticals (Basel)
December 2024
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain.
Food supplements are used for a variety of purposes, one of which is weight reduction. As excess weight is a long-term condition, some supplements are expected to be used for long periods of time. The long-term use of these dietary supplements makes it highly likely that they will be combined with medications, increasing the risk of food supplement-drug interactions, which are not always known or disclosed, and can lead to serious health problems, as has been observed.
View Article and Find Full Text PDFSevere Hypertension on the Background of Buspirone Use.
Hosp Pharm
January 2025
Vascular Medicine, Prairie Cardiovascular Institute Springfield, Springfield, IL, USA.
Drug-induced hypertension, though rare, often presents diagnostic challenges, particularly when the causative drug is not typically associated with hypertension. We describe a case involving a 55-year-old woman who presented with anxiety, confusion, and significantly high blood pressure unresponsive to standard treatments. Despite increasing medication doses, her blood pressure remained poorly controlled, leading to an investigation for secondary causes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!